Targeting menin for precision therapy in high-risk acute myeloid leukemia

被引：0
|
作者：
Jamil, Abdur [1 ]
Qureshi, Zaheer [2 ]
El-amir, Zain Mary [3 ]
Kupakuwana-Suk, Gillian [4 ]
Akram, Hamzah [5 ]
Ahmad, Mohsin [6 ]
Huselton, Eric [7 ]
机构：
[1] Samaritan Med Ctr, Dept Med, Watertown, NY 13601 USA
[2] Quinnipiac Univ, Frank H Netter MD Sch Med, Bridgeport, CT USA
[3] Univ Michigan, Ann Arbor, MI USA
[4] Univ Ottawa, Ottawa Hosp, Leukemia Fellowship Program, Dept Med,Div Hematol, Ottawa, ON, Canada
[5] Hamilton Hlth Sci, Hamilton, ON, Canada
[6] CHRISTUS Southeast Texas St Elizabeth Hosp, Beaumont, TX USA
[7] Univ Rochester, Dept Hematol Oncol, Rochester, NY USA
来源：
LEUKEMIA RESEARCH REPORTS | 2025年 / 23卷
关键词：
Acute myeloid leukemia; Revumenib; KMT2A; Menin inhibition therapy; INHIBITOR; REVUMENIB;
D O I：
10.1016/j.lrr.2024.100495
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objective: This mini-review provides an overview of the current evidence for Revumenib, a first-in-class menin inhibitor, in treating AML with KMT2A rearrangements or NPM1 mutations. This therapy represents a promising advancement by selectively disrupting leukemogenic pathways. Summary: The clinical promise of Revumenib in genetically defined AML highlights its potential role in shaping the future treatment landscape. This mini-review underscores the need for ongoing trials to define optimal dosing, safety protocols, and combination therapies, with the ultimate goal of establishing Revumenib as a standard of care for high-risk AML subsets.
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Code Status Transitions in Patients with High-Risk Acute Myeloid Leukemia (AML)
    Abrams, Hannah R.
    Nipp, Ryan D.
    Traeger, Lara
    Lavoie, Mitchell W.
    Reynolds, Matthew J.
    LeBlanc, Thomas W.
    El-Jawahri, Areej
    BLOOD, 2021, 138
  • [32] Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia
    Lin, Paul
    Veltri, Lauren Westfall
    Rezvani, Katy
    Oran, Betul
    Ahmed, Sairah
    Alatrash, Gheath
    Mehta, Rohtesh S.
    Rondon, Gabriela
    Kebriaei, Partow
    Popat, Uday
    Nieto, Yago
    Hosing, Chitra
    Jones, Roy B.
    Qazilbash, Muzaffar H.
    Khouri, Issa F.
    Shpall, Elizabeth J.
    Champlin, Richard E.
    Marin, David
    BLOOD, 2018, 132
  • [33] Code status transitions in patients with high-risk acute myeloid leukemia (AML).
    Abrams, Hannah Rebeccah
    Nipp, Ryan David
    Traeger, Lara
    Lavoie, Mitchell W.
    Reynolds, Matthew J.
    LeBlanc, Thomas William
    El-Jawahri, Areej
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] CPX-351 for the Treatment of High-Risk Patients with Acute Myeloid Leukemia
    Assi, Rita
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Ravandi, Farhad
    DiNardo, Courtney D.
    Kadia, Tapan M.
    Daver, Naval
    Jabbour, Elias J.
    Gborogen, Rosilyn A.
    Chamoun, Kamal
    Wierda, William G.
    Borthakur, Gautam
    Cortes, Jorge E.
    BLOOD, 2016, 128 (22)
  • [35] ENGINEERING IMMUNOTHERAPY RESISTANT HEMATOPOIESIS TO TREAT HIGH-RISK ACUTE MYELOID LEUKEMIA
    Casirati, G.
    Cosentino, A.
    Sereni, L.
    Cinella, V.
    Mucci, A.
    Brendel, C.
    Rambaldi, A.
    Armstrong, S.
    Genovese, P.
    HUMAN GENE THERAPY, 2022, 33 (7-8) : A8 - A8
  • [36] Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
    Zavras, Phaedon D. D.
    Sinanidis, Ilias
    Tsakiroglou, Panagiotis
    Karantanos, Theodoros
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (05)
  • [37] Clofarabine In Search of Combinations for the Treatment of Patients With High-Risk Acute Myeloid Leukemia
    Musto, Pellegrino
    Ferrara, Felicetto
    CANCER, 2008, 113 (08) : 1995 - 1998
  • [38] Interest of the association azacitidine–lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype
    E Scherman
    S Malak
    C Perot
    N C Gorin
    M T Rubio
    F Isnard
    Leukemia, 2012, 26 : 822 - 824
  • [39] Risk-Adapted Approaches to Therapy for High-Risk Acute Promyelocytic Leukemia
    Ranganathan, Aarati
    Powell, Bayard L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 : S135 - S138
  • [40] Targeting the spliceosome in high-risk B-cell acute lymphoblastic leukemia
    Murakami, Yuki
    Konishi, Hiroaki
    Tepper, Clifford
    McPherson, John
    Satake, Noriko
    CANCER RESEARCH, 2024, 84 (06)
12345